MF4
Dew can probably give you more details, but I've always liked the company. They have an approved drug, Sebivo, for HBV that is partnered with Novartis. The drug is approved in the U.S. and Europe and parts of the rest of the world. It was recently approved, so sales have not started to accelerate yet. I believe other drugs in the pipeline are also partnered with Novartis.
The company has about $160 million in cash, no debt, a good management team, a fine partner and an approved drug in a huge indication. Where in microcap (under a $250 million market cap) bio can you find a company with an approved product in a huge indication with a quality BP partner that has an enterprise value (EP) of around $50 million?
One caveat is that some brokerages houses that follow the stock may come out with downgrades--they always seem to come out with these reports after the damage has been done--that may hit the stock some more, so you may want to wait a bit. I'm not sure about this, though. I probably got in too early at $3.69.
Good luck on your investments. (Remember that this is always a lousy time of year for biotech--and this year we have the added pressure of the whole biogeneric thing plus the confluence of liberal Democrats and conservative Republicans aligned against the FDA and all shouting the mantra of "drug safety"--so hang in there.)
Bladerunner
Market Data 
Markets 
AI
